
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.4 20241031//EN" "JATS-archivearticle1-4-mathml3.dtd">
<article id="jocd70418" xml:lang="en" article-type="review-article" dtd-version="1.4"><?da-xref-anchor-style autodetect?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cosmet Dermatol</journal-id><journal-id journal-id-type="iso-abbrev">J Cosmet Dermatol</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="nlm-id">101130964</journal-id><journal-id journal-id-type="publisher-id">JOCD</journal-id><journal-title-group><journal-title>Journal of Cosmetic Dermatology</journal-title></journal-title-group><issn pub-type="ppub">1473-2130</issn><issn pub-type="epub">1473-2165</issn><?publisher_abbrev blackwell?><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12371607</article-id><article-id pub-id-type="pmcid-ver">PMC12371607.1</article-id><article-id pub-id-type="pmcaid">12371607</article-id><article-id pub-id-type="pmcaiid">12371607</article-id><article-id pub-id-type="pmid">40843925</article-id><article-id pub-id-type="doi">10.1111/jocd.70418</article-id><article-id pub-id-type="publisher-id">JOCD70418</article-id><article-id pub-id-type="other">5551372</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Axillary Hyperpigmentation Treatment: A Systematic Review of the Literature</article-title></title-group><contrib-group><contrib id="jocd70418-cr-0001" contrib-type="author"><name name-style="western"><surname>Vahabi</surname><given-names initials="SM">Seyed Mohammad</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4736-6803</contrib-id><xref rid="jocd70418-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jocd70418-cr-0002" contrib-type="author"><name name-style="western"><surname>Sajjadi</surname><given-names initials="S">Sajjad</given-names></name><xref rid="jocd70418-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jocd70418-cr-0003" contrib-type="author"><name name-style="western"><surname>Kalantari</surname><given-names initials="Y">Yasamin</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8443-4591</contrib-id><xref rid="jocd70418-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jocd70418-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jocd70418-cr-0004" contrib-type="author"><name name-style="western"><surname>Pourgholi</surname><given-names initials="E">Elnaz</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-4069-7289</contrib-id><xref rid="jocd70418-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jocd70418-cr-0005" contrib-type="author"><name name-style="western"><surname>Heidari</surname><given-names initials="S">Sama</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0005-2683-3750</contrib-id><xref rid="jocd70418-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jocd70418-cr-0006" contrib-type="author" corresp="yes"><name name-style="western"><surname>Etesami</surname><given-names initials="I">Ifa</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3026-2485</contrib-id><xref rid="jocd70418-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>ifa.etesami@gmail.com</email></address></contrib></contrib-group><aff id="jocd70418-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Dermatology, Razi Hospital, School of Medicine</named-content>
<institution>Tehran University of Medical Sciences</institution>
<city>Tehran</city>
<country country="IR">Iran</country>
</aff><aff id="jocd70418-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Dermatology, Venerology and Allergology</named-content>
<institution>Charité Universitätsmedizin Berlin</institution>
<city>Berlin</city>
<country country="DE">Germany</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Ifa Etesami (<email>ifa.etesami@gmail.com</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>8</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2025</year></pub-date><volume>24</volume><issue seq="40">8</issue><issue-id pub-id-type="pmc-issue-id">495392</issue-id><issue-id pub-id-type="doi">10.1111/jocd.v24.8</issue-id><elocation-id>e70418</elocation-id><history>
<date date-type="rev-recd"><day>09</day><month>8</month><year>2025</year></date>
<date date-type="received"><day>30</day><month>6</month><year>2025</year></date>
<date date-type="accepted"><day>16</day><month>8</month><year>2025</year></date>
</history><pub-history><event event-type="pmc-release"><date><day>22</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>26</day><month>08</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-08-26 00:25:17.650"><day>26</day><month>08</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">© 2025 The Author(s). <italic toggle="yes">Journal of Cosmetic Dermatology</italic> published by Wiley Periodicals LLC.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JOCD-24-e70418.pdf"><?pdf-name JOCD-24-e70418.pdf?><?pdf-size 855159?><?pdf-md5 33d5fc7b36bd218099f07727253aa4f0?><?pdf-image-server-status NEVER_LOAD?><?pdf-cloudpmc-urn urn:app:ac18/12371607/33d5fc7b36bd/JOCD-24-e70418.pdf?></self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:JOCD-24-e70418.pdf"/><abstract><title>ABSTRACT</title><sec id="jocd70418-sec-0001"><title>Introduction</title><p>Post‐inflammatory hyperpigmentation is a common dermatologic complaint that affects different parts of the body. Axillary hyperpigmentation (AH) is a common dermatologic complaint, with no standard treatment. We aim to address the efficacy and safety of the studied treatment modalities for AH.</p></sec><sec id="jocd70418-sec-0002"><title>Methods</title><p>A systematic search was done using “axillary” and “hyperpigmentation”‐related keywords/MeSH terms through PubMed/Medline, Scopus, Web of Science, and Embase.</p></sec><sec id="jocd70418-sec-0003"><title>Results</title><p>Ten studies on AH were categorized into topical treatments, light/laser‐based therapies, and comparative approaches. Topical agents like niacinamide, desonide, sweet orange extract, <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Perilla frutescens</italic>
</styled-content> leaf extract, <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Cyperus rotundus</italic>
</styled-content> oil, glycolic acid, and novel serums demonstrated varying degrees of pigmentation reduction, with desonide and <styled-content style="fixed-case" toggle="no">
<italic toggle="no">C. rotundus</italic>
</styled-content> oil showing significant effectiveness and minimal side effects. Q‐switched Nd:YAG laser was effective across three studies. Both Q‐switched Nd:YAG laser and intense pulsed light (IPL) modalities showed significant improvement with minimal adverse events; though pain was more reported with the laser. A comparative study found IPL superior to alpha‐hydroxy acid in skin lightening and texture improvement. One study on Curcuma aeruginosa was excluded due to its primary focus on hair growth reduction rather than pigmentation.</p></sec><sec id="jocd70418-sec-0004"><title>Conclusion</title><p>The most frequently used laser in treating AH was QS Nd‐YAG without having any severe adverse effect. Various topical treatments including Niacinamide, desonide, HQ, AHA, and a few herbal extracts were shown to be effective for AH.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jocd70418-kwd-0001">axillary hyperpigmentation</kwd><kwd id="jocd70418-kwd-0002">PIH</kwd><kwd id="jocd70418-kwd-0003">post‐inflammatory hyperpigmentation</kwd><kwd id="jocd70418-kwd-0004">Q‐switched Nd:YAG</kwd></kwd-group><counts><fig-count count="1"/><table-count count="1"/><page-count count="10"/><word-count count="6000"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>August 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.0 mode:remove_FC converted:22.08.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jocd70418-cit-1001">
<string-name name-style="western">
<given-names>S. M.</given-names>
<surname>Vahabi</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Sajjadi</surname>
</string-name>, <string-name name-style="western">
<given-names>Y.</given-names>
<surname>Kalantari</surname>
</string-name>, <string-name name-style="western">
<given-names>E.</given-names>
<surname>Pourgholi</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Heidari</surname>
</string-name>, and <string-name name-style="western">
<given-names>I.</given-names>
<surname>Etesami</surname>
</string-name>, “<article-title>Axillary Hyperpigmentation Treatment: A Systematic Review of the Literature</article-title>,” <source>Journal of Cosmetic Dermatology</source>
<volume>24</volume>, no. <issue>9</issue> (<year>2025</year>): <elocation-id>e70418</elocation-id>, <pub-id pub-id-type="doi">10.1111/jocd.70418</pub-id>.</mixed-citation>
</p><fn-group id="jocd70418-ntgp-0001"><fn fn-type="funding" id="jocd70418-note-0001"><p>
<bold>Funding:</bold> The authors received no specific funding for this work.</p></fn><fn fn-type="equal" id="jocd70418-note-0002"><p>Seyed Mohammad Vahabi and Sajjad Sajjadi contributed equally to this work as first authors.</p></fn></fn-group></notes></front><body id="jocd70418-body-0001"><sec id="jocd70418-sec-0005"><label>1</label><title>Introduction</title><p>Post‐inflammatory hyperpigmentation (PIH) is a common dermatologic complaint that affects different parts of the body. An international survey showed it affects almost 15% of the population; it is more prevalent in women [<xref rid="jocd70418-bib-0001" ref-type="bibr">1</xref>, <xref rid="jocd70418-bib-0002" ref-type="bibr">2</xref>]. It has prominent effects on patients' quality of life, social, and psychological status [<xref rid="jocd70418-bib-0001" ref-type="bibr">1</xref>, <xref rid="jocd70418-bib-0003" ref-type="bibr">3</xref>]. Different factors such as genetics, specific drugs, inflammation, and trauma such as sun exposure or acne play a role in the hyperpigmentation process. It usually appears as hyperpigmented macules or plaques, which can affect the dermis, epidermis, or both [<xref rid="jocd70418-bib-0002" ref-type="bibr">2</xref>, <xref rid="jocd70418-bib-0004" ref-type="bibr">4</xref>]. While PIH is a common cause of axillary pigmentation, it is important to consider and rule out other potential etiologies such as erythrasma, freckling, and genetically associated pigmentation disorders like neurofibromatosis type 1 and acanthosis nigricans. These conditions should receive proper treatment instead of lightening agents [<xref rid="jocd70418-bib-0005" ref-type="bibr">5</xref>, <xref rid="jocd70418-bib-0006" ref-type="bibr">6</xref>].</p><p>PIH pathogenesis is not fully explained yet, but there are several factors that affect it. Higher melanogenesis or melanin deposition in response to an inflammatory process or an external injury such as UV or shaving results in PIH. Damage in the basal layer of the epidermis, besides inflammatory markers like interleukin‐1, tumor necrosis factor (TNF), and epidermal growth factor (EGF) increases transport synthesis of melanin to the keratinocytes [<xref rid="jocd70418-bib-0007" ref-type="bibr">7</xref>].</p><p>There is no standard treatment for PIH conditions. Studies suggest that prevention by sunscreen and other methods is useful since the duration of treatment can vary up to 8 years [<xref rid="jocd70418-bib-0008" ref-type="bibr">8</xref>]. To date, there are several treatments for PIH, including topical steroids, niacinamide, retinoids, and laser or energy‐based device interventions [<xref rid="jocd70418-bib-0009" ref-type="bibr">9</xref>, <xref rid="jocd70418-bib-0010" ref-type="bibr">10</xref>]. These methods can also have adverse effects such as irritation or erythema in the affected area.</p><p>Axillary has a different tissue in comparison to other parts of the body. It has more sebaceous and sweat glands, more hair follicles, and a higher water loss value through the epidermis. This structure makes a weaker skin barrier in that part [<xref rid="jocd70418-bib-0011" ref-type="bibr">11</xref>]. Axillary hyperpigmentation (AH) is a dermatologic complaint, especially in women with darker skin. Hyperpigmentation in the axillary is more common than in other parts of the skin because of irritation and inflammation usually caused by body folds, friction, hair plucking, shaving, deodorants, and using whitening agents [<xref rid="jocd70418-bib-0011" ref-type="bibr">11</xref>, <xref rid="jocd70418-bib-0012" ref-type="bibr">12</xref>, <xref rid="jocd70418-bib-0013" ref-type="bibr">13</xref>]. Although there are different treatment options for skin pigmentation, there is no standard treatment for AH.</p><p>In this study, we aim to address the efficacy and safety of the studied treatment modalities for AH. This review study provides readers an overview of current treatment options for AH and helps them to make better treatment and research plans on this topic.</p></sec><sec sec-type="materials-and-methods" id="jocd70418-sec-0006"><label>2</label><title>Materials and Methods</title><p>The aim of this systematic study is to investigate the efficacy and safety of the studied treatment modalities for AH. It follows the 2020 guidelines of the Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA) [<xref rid="jocd70418-bib-0014" ref-type="bibr">14</xref>].</p><sec id="jocd70418-sec-0007"><label>2.1</label><title>Search Strategy</title><p>A systematic search was done using “axillary” and “hyperpigmentation”‐related keywords/MeSH terms through PubMed/Medline, Scopus, Web of Science, and Embase until June 1, 2025 (Data <xref rid="jocd70418-supitem-0001" ref-type="supplementary-material">S1</xref>).</p></sec><sec id="jocd70418-sec-0008"><label>2.2</label><title>Eligibility Criteria and Study Selection</title><p>The inclusion criteria were studies in which they investigated the efficacy of a treatment for AH in healthy adults. The exclusion criteria were as follows: hyperpigmentation in other areas, presence of a systemic disease, or any skin conditions that are a sign of other diseases like Acanthosis nigricans, immunocompromised patients, a history of skin cancer or keloid, and skin infection (Figure <xref rid="jocd70418-fig-0001" ref-type="fig">1</xref>).</p><fig position="float" fig-type="FIGURE" id="jocd70418-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) flow chart of the number of studies identified and selected into the systematic review and meta‐analysis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="JOCD-24-e70418-g001.jpg"><?image-name JOCD-24-e70418-g001.jpg?><?image-size 100721?><?image-md5 1fe585c345556ee3b142b366294e73a9?><?image-image-server-status LOAD_COMPLETED?><?image-original-height 1026?><?image-original-width 1064?><?image-scaled-height 684?><?image-scaled-width 709?><?image-cloudpmc-urn urn:cdn:blobs/ac18/12371607/1fe585c34555/JOCD-24-e70418-g001.jpg?><?thumb-name JOCD-24-e70418-g001.gif?><?thumb-size 12300?><?thumb-md5 dfdbea141fd7edd6f42dcdcd7757de17?><?thumb-image-server-status NEVER_LOAD?><?thumb-scaled-height 96?><?thumb-scaled-width 100?><?thumb-cloudpmc-urn urn:cdn:blobs/ac18/12371607/dfdbea141fd7/JOCD-24-e70418-g001.gif?></graphic></fig><p>For the quality of included papers, we used the National Heart, Lung, and Blood Institute (NHLBI) quality assessment tools, and the quality of the included studies was assessed by two reviewers. This tool assesses the quality of papers in terms of methodology, report of the findings, and possible distortions based on a questionnaire checklist (Data <xref rid="jocd70418-supitem-0002" ref-type="supplementary-material">S2</xref> and <xref rid="jocd70418-supitem-0003" ref-type="supplementary-material">S3</xref>).</p></sec><sec id="jocd70418-sec-0009"><label>2.3</label><title>Data Extraction</title><p>Four independent reviewers screened the articles to exclude irrelevant ones. In case of disagreement, a fifth reviewer made the final decision. Extracted data included study characteristics, patient age, sex, Fitzpatrick score, treatment modality, outcome measurement, outcomes, and possible adverse effects.</p></sec></sec><sec sec-type="results" id="jocd70418-sec-0010"><label>3</label><title>Results</title><p>Ten articles were enrolled (Table <xref rid="jocd70418-tbl-0001" ref-type="table">1</xref>). The retrieved articles are categorized into three groups: “topical treatments,” “light‐ and laser‐based modalities,” and “comparing topical and light‐ and laser‐based modalities.”</p><table-wrap position="float" id="jocd70418-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Characteristics of the included studies.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Study design</th><th align="center" valign="bottom" rowspan="1" colspan="1">Population age, sex Fitzpatrick score</th><th align="center" valign="bottom" rowspan="1" colspan="1">Treatment</th><th align="center" valign="bottom" rowspan="1" colspan="1">Outcome measure</th><th align="center" valign="bottom" rowspan="1" colspan="1">Outcome</th><th align="center" valign="bottom" rowspan="1" colspan="1">Adverse effect</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="6" valign="top" rowspan="1">
<bold>Topical treatments</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Castanedo‐Cazares et al. [<xref rid="jocd70418-bib-0015" ref-type="bibr">15</xref>] (2013), RCT</td><td align="center" valign="top" rowspan="1" colspan="1">24 females, 19–24 (Mean 21), III (21%), IV (46%), V (33%)</td><td align="center" valign="top" rowspan="1" colspan="1">Niacinamide 4%, desonide 0.05%, or placebo daily every night for 9 weeks.</td><td align="center" valign="top" rowspan="1" colspan="1">Tristimulus colorimeter (Chromameter CR‐300, Minolta, Osaka, Japan), histologic evaluation.</td><td align="center" valign="top" rowspan="1" colspan="1">Both modalities were more effective in comparison with placebo (<italic toggle="yes">p</italic> = 0.03); However, desonide showed a better depigmenting effect than niacinamide (<italic toggle="yes">p</italic> = 0.002). A good to excellent response was observed in 30% of desonide, 24% of cases for niacinamide, and 6% for placebo.</td><td align="center" valign="top" rowspan="1" colspan="1">None.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Colpas et al. [<xref rid="jocd70418-bib-0016" ref-type="bibr">16</xref>] (2019), Observational</td><td align="center" valign="top" rowspan="1" colspan="1">33 females, 18–58, NA</td><td align="center" valign="top" rowspan="1" colspan="1">Patients applied the serum in one axilla and the cream to the other twice a day for 90 days. Serum containing CG‐TGP2, nicotinamide, 4‐butyl‐resorcinol, N‐undecylenoyl phenylalanine and dihydroavenanthramide compared with a cream containing nicotinamide, arbutin, bisabolol and retinaldehyde.</td><td align="center" valign="top" rowspan="1" colspan="1">Dermatologic exam, photographic analysis, skin colorimetry.</td><td align="center" valign="top" rowspan="1" colspan="1">Based on L colorimetric analysis, the area treated with serum showed a 62.5% improvement in skin whitening, compared to a 33.14% improvement in the area treated with cream. Overall, there was no significant difference between two products.</td><td align="center" valign="top" rowspan="1" colspan="1">NA.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Preedalikit et al. [<xref rid="jocd70418-bib-0017" ref-type="bibr">17</xref>] (2020), Observational</td><td align="center" valign="top" rowspan="1" colspan="1">30 females, 20–55, III–IV</td><td align="center" valign="top" rowspan="1" colspan="1">The PFLE was formulated as an underarm serum (PL serum) and applied twice daily for 4 weeks.</td><td align="center" valign="top" rowspan="1" colspan="1">The efficacy was evaluated on B16F10 cell line, and healthy volunteers. Changes in skin melanin and erythema index.</td><td align="center" valign="top" rowspan="1" colspan="1">A gradual decrease in melanin index from 37.94 ± 0.66 to 35.90 ± 0.64 (5.38%), and a significant decrease in erythema index from 11.32 ± 0.79 to 10.21 ± 0.11 (9.80%) were observed during a 4‐week period.</td><td align="center" valign="top" rowspan="1" colspan="1">None.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mohammed [<xref rid="jocd70418-bib-0018" ref-type="bibr">18</xref>] (2022), RCT</td><td align="center" valign="top" rowspan="1" colspan="1">153 females, 19–32, III (16%), IV (52%), V (32%)</td><td align="center" valign="top" rowspan="1" colspan="1">First group received 0.25 mL <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Cyperus rotundus</italic>
</styled-content> oil twice daily. Participants in Groups 2 (HQ) and 3 (cold cream) implemented the same amount and procedure with HQ 4% and placebo.</td><td align="center" valign="top" rowspan="1" colspan="1">A tri‐stimulus colorimeter. Physician Global Assessment, self‐assessment questionnaire.</td><td align="center" valign="top" rowspan="1" colspan="1">Both modalities were effective (<italic toggle="yes">p</italic> &lt; 0.05) with similar efficacy.</td><td align="center" valign="top" rowspan="1" colspan="1">82% of the HQ group reported erythema and irritation, and 48% reported itching.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Murlistyarini et al. [<xref rid="jocd70418-bib-0019" ref-type="bibr">19</xref>] (2022), Case report</td><td align="center" valign="top" rowspan="1" colspan="1">2 females, 23–24, III</td><td align="center" valign="top" rowspan="1" colspan="1">During 8 weeks patients applied 8% GA cream every night and two sessions of peeling with 15% GA were performed for each.</td><td align="center" valign="top" rowspan="1" colspan="1">Von Luschan's chromatic scale assessed by 3 evaluators.</td><td align="center" valign="top" rowspan="1" colspan="1">The hyperpigmentation scores in first patient decreased from 23 to 14 and 20 to 10 in second patient. Both patients reported satisfactory improvements.</td><td align="center" valign="top" rowspan="1" colspan="1">None.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Oei et al. [<xref rid="jocd70418-bib-0020" ref-type="bibr">20</xref>] (2024), Observational</td><td align="center" valign="top" rowspan="1" colspan="1">32 females, 18–25, NA</td><td align="center" valign="top" rowspan="1" colspan="1">Patients applied one fingertip of sweet orange peels (<styled-content style="fixed-case" toggle="no">
<italic toggle="no">Citrus sinensis</italic>
</styled-content> L.) 0.1% extract cream twice daily for 8 weeks and evaluation conducted every 2 weeks.</td><td align="center" valign="top" rowspan="1" colspan="1">Melanin index, Physician global assessment (PGA).</td><td align="center" valign="top" rowspan="1" colspan="1">The melanin index was initially 349.04 ± 109.84 AU which decreased to 253.06 ± 96.36 AU after 8 weeks of treatment. (<italic toggle="yes">p</italic> &lt; 0.001). According to the Physician Global Assessment 68.8% of patients showed mild improvement (26%–50%) and 25% experienced good improvement (51%–75%).</td><td align="center" valign="top" rowspan="1" colspan="1">None.</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">
<bold>Light and laser‐based modalities</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ghannam et al. [<xref rid="jocd70418-bib-0021" ref-type="bibr">21</xref>] (2017), Observational</td><td align="center" valign="top" rowspan="1" colspan="1">17 females, 19–48 (Mean 34.27 ± 9.24), IV–V</td><td align="center" valign="top" rowspan="1" colspan="1">QS treatment was performed every 2 weeks. The number of treatments varied between 3 and 12 sessions.</td><td align="center" valign="top" rowspan="1" colspan="1">Standardized grading scale.</td><td align="center" valign="top" rowspan="1" colspan="1">Good improvement score of 4 ± 0.44 (51% to 75% change).</td><td align="center" valign="top" rowspan="1" colspan="1">Hypopigmentation in one patient was observed.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Robredo [<xref rid="jocd70418-bib-0012" ref-type="bibr">12</xref>] (2020), Observational</td><td align="center" valign="top" rowspan="1" colspan="1">9 females, 20–52, IV–V</td><td align="center" valign="top" rowspan="1" colspan="1">Four sessions of nanosecond 1064 nm Q‐switched Nd:YAG treatment every 2 weeks.</td><td align="center" valign="top" rowspan="1" colspan="1">Pigmentary changes of PIH lesion compared to non‐affected regions and GIAS satisfaction assessment, pain visual analogue scale (VAS) scoring.</td><td align="center" valign="top" rowspan="1" colspan="1">All axillae responded to the laser treatment, showing an 85%–100% reduction in pigmentation across the lesion area. Global Aesthetic Improvement Scale (GAIS) satisfaction ratings indicated 22%–33% of patients achieved excellent improvement, while 55% experienced significant improvement.</td><td align="center" valign="top" rowspan="1" colspan="1">None.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Amornpetkul et al. [<xref rid="jocd70418-bib-0022" ref-type="bibr">22</xref>] (2021), Observational</td><td align="center" valign="top" rowspan="1" colspan="1">22 females, 20–60, III: 2 (9.1%), IV: 20 (90.9%)</td><td align="center" valign="top" rowspan="1" colspan="1">Each individual received five split‐side treatments every 2 weeks.</td><td align="center" valign="top" rowspan="1" colspan="1">Melanin index (MI), color chart level using the Pantone SkinToneTM Guide, im‐ provement grading scale (IGS), patient satisfaction scores.</td><td align="center" valign="top" rowspan="1" colspan="1">Both treatments significantly improved after three sessions. There was no significant difference in MI, color chart level, IGS, and patient satisfaction scores between two treatments.</td><td align="center" valign="top" rowspan="1" colspan="1">Regarding IPL, Hyperpigmentation in 1 (4.45%) after, erythema in 1 (4.45%). No side effects were observed in the QS‐treated group.</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">
<bold>Comparing topical and light and laser‐based modalities</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Jarritrum et al. [<xref rid="jocd70418-bib-0023" ref-type="bibr">23</xref>] (2014), Observational</td><td align="center" valign="top" rowspan="1" colspan="1">20 females, 24–30 (Mean 29), III:3/20, IV: 9/20, and VI: 8/20</td><td align="center" valign="top" rowspan="1" colspan="1">One underarm side was treated with 40% AHA. The other underarm side was treated with IPL wavelength of 530 nm. Patients received biweekly treatment for five times.</td><td align="center" valign="top" rowspan="1" colspan="1">Skin color level of underarms, the satisfaction of volunteer.</td><td align="center" valign="top" rowspan="1" colspan="1">AHA treatment enhanced skin color 65% and 35% for one level and two levels, respectively. Meanwhile, IPL treatment improved skin color 30% for one level and 70% for two levels. The improvement of skin smoothness was 5% and 45% for AHA and IPL, respectively. The evaluation of satisfaction after treatment showed that the participants in this project are pleased with IPL 15% more than AHA.</td><td align="center" valign="top" rowspan="1" colspan="1">None.</td></tr></tbody></table><table-wrap-foot id="jocd70418-ntgp-0002"><fn id="jocd70418-note-0003"><p>Abbreviations: AHA, Alpha Hydroxy Acid; GA, Glycolic acid; HQ, hydroquinone; IPL, Intense Pulsed Light; PFLE, <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Perilla frutescens</italic>
</styled-content> L. leaves extract; QS, Q‐switched Nd:YAG laser.</p></fn></table-wrap-foot></table-wrap><sec id="jocd70418-sec-0011"><label>3.1</label><title>Topical Treatments</title><p>Six studies fell under the category of topical treatments. One study compared the effectiveness of 4% niacinamide with 0.05% desonide, while another assessed the efficacy of <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Cyperus rotundus</italic>
</styled-content> oil in combination with hydroquinone (HQ). A third article investigated the effectiveness of <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Perilla frutescens</italic>
</styled-content> L. leaf extract (PFLE) serum. Another study compared two novel topical formulations. One study evaluated the effects of sweet orange extract, and the final study examined the impact of glycolic acid.</p><p>In a study by Castanedo‐Cazares et al. [<xref rid="jocd70418-bib-0015" ref-type="bibr">15</xref>] on 24 female patients (women from tropical areas including Latin America with Fitzpatrick III to V), patients randomly received niacinamide 4%, desonide 0.05%, or placebo every night for 9 weeks to treat AH. Both niacinamide and desonide demonstrated greater effectiveness compared to placebo (<italic toggle="yes">p</italic> = 0.03); however, in terms of depigmenting effect, desonide had a better effect (<italic toggle="yes">p</italic> = 0.002). A good to excellent result was observed in 30% of desonide, 24% of niacinamide, and 6% of placebo. No adverse effect was noted.</p><p>In an RCT by Mohammed et al. [<xref rid="jocd70418-bib-0018" ref-type="bibr">18</xref>], they compared the effectiveness of <styled-content style="fixed-case" toggle="no">
<italic toggle="no">C. rotundus</italic>
</styled-content> essential oil (CREO) HQ 4% with placebo (cold cream). 153 participants (Fitzpatrick III to V) after 12 weeks of treatment were assessed based on colorimetric values measured by a colorimeter (Chromameter CR‐300; Minolta, Osaka, Japan). Both CREO (12.8 ± 6.1 to 7.4 ± 3.4 [<italic toggle="yes">p</italic> &lt; 0.001]) and HQ (10.9 ± 4.7 to 7.8 ± 1.5 [<italic toggle="yes">p</italic> &lt; 0.001]) showed better depigmenting effects than placebo (12.6 ± 4.3 to 12.8 ± 4.3 [<italic toggle="yes">p</italic> = 0.9]). No significant difference in terms of depigmentation efficacy was observed (<italic toggle="yes">p</italic> &gt; 0.05). In terms of anti‐inflammatory and hair growth reduction effects, CREO was significantly more effective (<italic toggle="yes">p</italic> &lt; 0.05). Regarding the adverse events, 82% of the HQ group noted erythema and irritation, and 48% noted pruritus. In contrast, none of the patients treated with CREO complained of erythema or itching. Notably, one patient (2%) reported an unpleasant smell associated with CREO.</p><p>In a study carried out by Oei et al. [<xref rid="jocd70418-bib-0020" ref-type="bibr">20</xref>] in 2024, the extract of sweet orange was formulated into a cream. Sweet orange contains polyphenols, vitamin A, vitamin E, and ascorbic acid, and its peel exhibits an anti‐tyrosinase effect. Tyrosinase plays a main role in melanogenesis. The cream was applied twice daily to both axillae for 8 weeks and assessed every 2 weeks. At the end, the melanin index decreased from 349.04 ± 109.84 arbitrary unit (AU) to 253.06 ± 96.36 AU (<italic toggle="yes">p</italic> &lt; 0.001). Hyperpigmentation evaluated by global physician assessment revealed 68.8% of patients showed mild improvement (26%–50%), and 25% experienced good improvement (51%–75%).</p><p>Colpas et al. [<xref rid="jocd70418-bib-0016" ref-type="bibr">16</xref>] compared a serum containing Oligopeptide‐34 (CG‐TGP2), nicotinamide, 4‐butyl‐resorcinol, N‐undecylenoyl phenylalanine, and dihydroavenanthramide and a cream containing nicotinamide, arbutin, bisabolol, and retinaldehyde. There was no significant difference between the two; but based on L colorimetric value, the serum showed a better improvement (62.5%) (<italic toggle="yes">p</italic> &lt; 0.001) compared to the cream (33.14%) (<italic toggle="yes">p</italic> &lt; 0.001).</p><p>Preedalikit et al. [<xref rid="jocd70418-bib-0017" ref-type="bibr">17</xref>] evaluated the effect of <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Perilla frutescens</italic>
</styled-content> L. leaves extract (PFLE) serum on axillary brightening and melanogenesis in 30 Thai participants (Fitzpatrick III to V) who applied the serum twice daily for 4 weeks. A significant reduction in melanin index (37.94 ± 0.66 to 35.90 ± 0.64 (5.38%) [<italic toggle="yes">p</italic> &lt; 0.05]) was observed; the agent improved AH without skin irritation.</p><p>Murlistyarini et al. [<xref rid="jocd70418-bib-0019" ref-type="bibr">19</xref>] performed a case study involving two female patients with a Fitzpatrick score of III. Each patient applied 8% glycolic acid cream every night and underwent two sessions of 15% glycolic acid peeling at Weeks 2 and 6. By Week 8, the hyperpigmentation score decreased from 23 to 14 in the first patient and from 20 to 10 in the second.</p></sec><sec id="jocd70418-sec-0012"><label>3.2</label><title>Light and Laser‐Based Devices</title><p>Three studies were included in this category; all of which evaluated the effectiveness of the Q‐switched Nd:YAG laser, and one of these studies compared its efficacy with intense pulsed light (IPL).</p><p>In a study carried out by Ghannam et al. [<xref rid="jocd70418-bib-0021" ref-type="bibr">21</xref>], 17 female patients (Fitzpatrick IV and V) received Q‐switched Nd:YAG laser (Spectra VRM, Lutronic, Ilsan, Gyeonggi, South Korea) every 2 weeks. The treatment protocol included a pulse repetition rate of 10 Hz, a 5 ns pulse width, an 8 mm spot size, and a fluence of 1.4 J/cm<sup>2</sup>, with two passes over the entire area with 20%–30% overlap. Subsequently, the laser was set on micro‐pulsed Spectra mode with a 7 mm spot size, 3 laser passes, 300 ns pulse width, and 20%–40% overlap. The results showed a good improvement in scores (4 ± 0.44; range: 4–5). In order to reach an excellent patient‐evaluated improvement, a minimum number of 3 treatment sessions was required; though increasing the number of sessions did not necessarily improve the results. Regarding adverse effects, hypopigmentation was observed in one patient.</p><p>The next study performed by Robredo et al. [<xref rid="jocd70418-bib-0012" ref-type="bibr">12</xref>], 9 Filipino females with a Fitzpatrick score of IV to V underwent four sessions of nanosecond 1064 nm Q‐switched Nd:YAG 1064 nm (Alma Q, Alma Lasers GmbH, Nurnberg, Germany) treatment every 2 weeks. The treatment protocol consisted of four passes, a 7 mm spot size, and a fluence of 2.6 mJ/cm<sup>2</sup> until total energy reached 800 kJ. All patients demonstrated good results and pigmentation reduction in 85%–100% of lesions. The Global Aesthetic Improvement Scale (GIAS) satisfaction score revealed 22%–33% excellent improvement and 55% much improved scores. No adverse effects were observed.</p><p>The last study [<xref rid="jocd70418-bib-0022" ref-type="bibr">22</xref>] compared the efficacy of Q‐switched Nd:YAG laser (frequency of 10 Hz, fluence of 2.0–2.5 J/cm<sup>2</sup>, 3–5 passes, and spot size of 6 mm) with IPL (550–1200 nm, spot size 30 mm, single‐shot, and 5–8 J/cm<sup>2</sup> fluence, with 1 pass treatment). Amornpetkul et al. conducted an RCT with 22 patients (Fitzpatrick III to IV), and all participants received five split‐sided therapies every 2 weeks. Both treatments demonstrated significant improvement from baseline. No significant difference was observed in the improvement grading scale (IGS) (<italic toggle="yes">p</italic> = 0.879) (2.35 ± 1.01 (25% improvement) for the IPL and 2.4 ± 1.02 (25% improvement) for the Q‐switched Nd:YAG laser). The skin color level did not differ significantly between modalities (<italic toggle="yes">p</italic> = 0.673) (8.41 ± 2.17 at baseline to 7.47 ± 1.58 for IPL and 8.27 ± 1.98 to 7.58 ± 1.57 for the Q‐switched Nd:YAG laser). There was no significant difference in the reduction in the MI for <italic toggle="yes">p</italic> = 0.811 (from 533.64 ± 28.78 at baseline to 528.37 ± 31.97 for IPL and from 533.63 ± 31.55 to 529.06 ± 29.13 for the Q‐switched Nd:YAG laser). VAS for the IPL (8.31 ± 1.7) and the QS (8.22 ± 1.7) did not differ significantly (<italic toggle="yes">p</italic> = 0.707). The QS group complained of more pain than the IPL group. In the IPL‐treated group, erythema 1 day after the therapy in one patient (4.45%) and hyperpigmentation in another patient (4.45%) 2 weeks after the second IPL were noted.</p></sec><sec id="jocd70418-sec-0013"><label>3.3</label><title>Comparing Topical and Light and Laser‐Based Modalities</title><p>Jarritrum et al. [<xref rid="jocd70418-bib-0023" ref-type="bibr">23</xref>] evaluated the effectiveness of Alpha Hydroxy Acid (AHA) 40% and IPL (wavelength of 530 nm) for the treatment of AH on 20 patients receiving 5 treatments with 2‐week intervals. One underarm side was treated with AHA, and the other was treated with IPL. Regarding AHA, in 65% of patients, the skin color was enhanced by one level, and in 35% of patients, it was improved by two levels. IPL enhanced skin color by one level in 30% and by two levels in 70% of patients. Skin smoothness was enhanced by 5% and 45% for AHA and IPL, respectively.</p><p>One‐month post‐therapy, AHA revealed one level of skin color recovery in 30% and a 30% reduction in skin smoothness; while IPL showed no change.</p><p>Regarding side effects, skin redness, burning surface, and itching were most commonly observed in the group treated with AHA (100%) after the first treatment. Also, dry and flaking skin was noted in the group treated with AHA. Regarding IPL, skin redness, dry skin, and itch were reported.</p><p>It is worth mentioning that we found one clinical trial on 60 females that primarily evaluated the effect of Curcuma aeruginosa Roxb. essential oil for slowing the growth of hair and found that this treatment also lightens the axillary region. Patients received the agent for 10 weeks; after that, they received a placebo for 2 weeks [<xref rid="jocd70418-bib-0024" ref-type="bibr">24</xref>]. Since we exclusively included the studies that primarily focused on AH treatments, this study was excluded from our manuscript.</p></sec></sec><sec sec-type="discussion" id="jocd70418-sec-0014"><label>4</label><title>Discussion</title><p>In this study, we found that both topical in addition to light and laser‐based therapies are effective. The studied topical agents for AH were niacinamide, desonide, CREO, AHA, HQ, <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Citrus Sinensis</italic>
</styled-content> L., and PFLE. Light and laser therapies applied for AH were QS‐Nd YAG and IPL. Many of these treatments are being used off‐label for AH.</p><p>AH is a very common aesthetic complaint, especially in dark‐skinned women. Skin barriers are weaker in the axillary area because of higher water loss through the epidermis and the presence of more sebaceous and sweat glands. Also, using chemical deodorants, shaving, and friction cause irritation and skin tissue damage, which result in PIH [<xref rid="jocd70418-bib-0011" ref-type="bibr">11</xref>, <xref rid="jocd70418-bib-0022" ref-type="bibr">22</xref>, <xref rid="jocd70418-bib-0025" ref-type="bibr">25</xref>]. In a study evaluating the histopathology of hyperpigmented axillae in Filipino patients, they hypothesized that darkening of the axillary is mild PIH. It is characterized by skin irritation or stimulation (mostly by hair plucking), which results in a melanin increase in the epidermis [<xref rid="jocd70418-bib-0013" ref-type="bibr">13</xref>].</p><p>However, there exist no gold standard treatments for it. According to literature, it has been proposed that AH is a type of PIH. There exist various treatment strategies for PIH, including topical therapy, including hydroquinone, which is commonly combined with topical retinoid and steroid, as in Kligman formula, chemical peels such as Glycolic and salicylic acid, and laser therapies including Q‐switched ruby, picosecond, and Q‐switched Nd:YAG lasers [<xref rid="jocd70418-bib-0026" ref-type="bibr">26</xref>]. Applying lasers in dermatologic diseases has a wide spectrum. Among these, we can mention hair removal, scar treatment, rejuvenation, post‐acne erythema, tattoo removal, and skin pigmentation conditions [<xref rid="jocd70418-bib-0027" ref-type="bibr">27</xref>, <xref rid="jocd70418-bib-0028" ref-type="bibr">28</xref>, <xref rid="jocd70418-bib-0029" ref-type="bibr">29</xref>, <xref rid="jocd70418-bib-0030" ref-type="bibr">30</xref>].</p><p>Pablo et al. compared the effectiveness and safety of niacinamide, desonide, and placebo in treating AH in an RCT with 24 females. Niacinamide has anti‐inflammatory effects that cause depigmentation by prohibiting the melanosomes from going from the melanocyte to the keratinocyte [<xref rid="jocd70418-bib-0031" ref-type="bibr">31</xref>]. Desonide is a synthetic, low‐potency corticosteroid and is generally considered safe. Topical corticosteroids can also reduce the PIH and cause depigmentation. The results of that study showed that both agents were effective; however, desonide had a superior blanching impact. They also proposed that desonide might decrease the inflammation involving the basal membrane disruption or stop the pathways which postpone the recovery. No change in the melanocyte count was noted, and they concluded that melanogenesis relies on enhanced melanin production and not on the cell number alterations [<xref rid="jocd70418-bib-0032" ref-type="bibr">32</xref>].</p><p>In another study with 153 participants, the efficacy of CREO, HQ, and placebo was compared. The oil of the grass <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Cyperus rotundus</italic>
</styled-content> (purple nutsedge) has anti‐inflammatory in addition to antipigmenting effects (as effective as HQ) and it inhibits tyrosinase activity. The authors of that study concluded that CREO had significantly better anti‐inflammatory and depigmenting effects and a decrease in hair growth compared to HQ. Cyperus rotundus has anti‐inflammatory and antioxidant effects because of its polyphenol, tannin, and flavonoid components [<xref rid="jocd70418-bib-0033" ref-type="bibr">33</xref>, <xref rid="jocd70418-bib-0034" ref-type="bibr">34</xref>]. It also showed inhibitory effects on melanogenesis in B16F10 melanoma cells [<xref rid="jocd70418-bib-0035" ref-type="bibr">35</xref>].</p><p>Another study examined the efficacy of PFLE serum (<styled-content style="fixed-case" toggle="no">
<italic toggle="no">Perilla frutescens</italic>
</styled-content> L. leaves extract) on α‐melanocyte‐stimulation hormone (α‐MSH), which is a chemical involved in melanogenesis. This herbal medicine product contains a variety of potent antioxidants in leaves, having various biological effects. The results showed that this serum is effective in axillary whitening and causes a significant reduction in melanin and the erythema index in comparison to baseline and improves the skin tone [<xref rid="jocd70418-bib-0017" ref-type="bibr">17</xref>].</p><p>Two other reports showed the efficacy of glycolic acid and sweet orange peel. Glycolic acid with modified pH showed to have anti‐inflammatory and epidermal renewal and collagen production stimulative effects [<xref rid="jocd70418-bib-0036" ref-type="bibr">36</xref>]. Sweet orange peel has flavonoid components, which affect melanin production through their tyrosinase enzyme inhibitory nature. These components can inhibit melanogenesis [<xref rid="jocd70418-bib-0037" ref-type="bibr">37</xref>, <xref rid="jocd70418-bib-0038" ref-type="bibr">38</xref>]. Also, hesperidin, another component in citrus peels, showed inhibition of melanin synthesis in melanoma B16 cells [<xref rid="jocd70418-bib-0039" ref-type="bibr">39</xref>].</p><p>Two observational studies exclusively investigated the use of Q‐switched Nd:YAG on AH, and another study compared Q‐switched Nd:YAG with IPL. The first observational study on nine patients [<xref rid="jocd70418-bib-0012" ref-type="bibr">12</xref>] evaluating the use of nanosecond 1064 nm Q‐switched Nd:YAG showed that 33.3% of individuals had excellent results, and 55.5% manifested significant enhancement in AH. In this regard, Ghannam et al.'s observational study on 17 females showed that low‐fluence Q‐switched 1064‐nm Nd:YAG laser is a good treatment option for AH [<xref rid="jocd70418-bib-0021" ref-type="bibr">21</xref>]. They proposed that it leads to good‐to‐excellent enhancement after a minimum of 3 sessions. Additionally, it was concluded that the outcome was not related to increased session numbers. It has been shown that QS laser can decrease melanin granules and melanosomes and is effective for treating various pigmentation diseases, namely melasma, as revealed by histologic studies [<xref rid="jocd70418-bib-0040" ref-type="bibr">40</xref>].</p><p>Regarding comparison of Q‐switched Nd:YAG and IPL for AH, an study on 22 participants was conducted by Amornpektul et al. [<xref rid="jocd70418-bib-0022" ref-type="bibr">22</xref>]. The result of that study suggested that both modalities are useful with no significant difference in the result. IPL showed a lower level of pain during the procedure compare to Q‐switched Nd:YAG. A serious adverse effect of IPL, especially in patients with darker skin, is hyperpigmentation; however, it is rare [<xref rid="jocd70418-bib-0022" ref-type="bibr">22</xref>]. Previous studies showed efficacy and safety of IPL in treatment of hyperpigmentations in other parts of the body [<xref rid="jocd70418-bib-0041" ref-type="bibr">41</xref>, <xref rid="jocd70418-bib-0042" ref-type="bibr">42</xref>, <xref rid="jocd70418-bib-0043" ref-type="bibr">43</xref>]. Due to being cost–benefit and commonly used in dermatology, IPL seems to be a very good choice for AH.</p><p>One study [<xref rid="jocd70418-bib-0023" ref-type="bibr">23</xref>] evaluated the efficacy of IPL and AHA on 20 subjects. AHA is a chemical peeling agent belonging to a group of organic acids. Furthermore, it has been suggested that AHA can inhibit the tyrosinase enzyme. The results of that study showed that both of these modalities are effective in lightening axillae and rejuvenating underarm skin and enhancing smoothness. However, IPL was more effective than AHA regarding whiteness (85%) and smoothness (30%), respectively. Moreover, adverse effects of AHA were more serious than those of IPL due to the high concentration (40%) of AHA and low pH of 2.</p><p>Although our study is a comprehensive review of available treatments for AH, it also has limitations. The available studies on this topic are limited, mostly with small sample sizes and short follow‐up periods. There is also a lot of variation in treatment methods, which made us unable to do a meta‐analysis. These limitations are due to the lack of standard treatment for AH and the few published studies on this topic.</p><p>In conclusion, all topical, light, and laser‐based devices are useful treatments for AH. The most frequently used laser in treating AH was QS Nd‐YAG without having any severe adverse effects. Various topical treatments, including niacinamide, desonide, HQ, AHA, and a few herbal extracts, were shown to be effective for AH. However, based on this review, very few studies are available in the literature, and larger randomized studies in this field are essentially needed. This study shed light on current available treatments, as well as giving ideas to readers to conduct new studies in the future to improve treatment outcomes and potential innovations.</p></sec><sec id="jocd70418-sec-0016"><title>Author Contributions</title><p>Conceptualization: I.E., Y.K., S.M.V.; data curation: S.S., E.P., S.H.; methodology: S.S., E.P.; supervision: I.E., S.M.V.; validation: S.H., Y.K.; writing – original draft preparation: S.M.V., S.S., Y.K., E.P.; writing – review and editing: S.M.V., I.E., S.H. All authors have read and agreed to the published version of the manuscript.</p></sec><sec sec-type="COI-statement" id="jocd70418-sec-0015"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="jocd70418-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Data S1:</bold> Search query.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="JOCD-24-e70418-s002.docx" position="float" orientation="portrait"><?suppdata-name JOCD-24-e70418-s002.docx?><?suppdata-size 13754?><?suppdata-md5 8f4f39d703a8c157d1abfd3fdbf2cdbc?><?suppdata-image-server-status NEVER_LOAD?><?suppdata-mime-type application?><?suppdata-mime-sub-type vnd.openxmlformats-officedocument.wordprocessingml.document?><?suppdata-cloudpmc-urn urn:app:ac18/12371607/8f4f39d703a8/JOCD-24-e70418-s002.docx?></media></supplementary-material><supplementary-material id="jocd70418-supitem-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Data S2:</bold> Quality assessment E.P.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="JOCD-24-e70418-s001.docx" position="float" orientation="portrait"><?suppdata-name JOCD-24-e70418-s001.docx?><?suppdata-size 37059?><?suppdata-md5 94788a8b0e09fcdac30833b4034d87ca?><?suppdata-image-server-status NEVER_LOAD?><?suppdata-mime-type application?><?suppdata-mime-sub-type vnd.openxmlformats-officedocument.wordprocessingml.document?><?suppdata-cloudpmc-urn urn:app:ac18/12371607/94788a8b0e09/JOCD-24-e70418-s001.docx?></media></supplementary-material><supplementary-material id="jocd70418-supitem-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Data S3:</bold> Quality assessment S.S.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="JOCD-24-e70418-s003.docx" position="float" orientation="portrait"><?suppdata-name JOCD-24-e70418-s003.docx?><?suppdata-size 38345?><?suppdata-md5 31473074bddb603700829f1399aba547?><?suppdata-image-server-status NEVER_LOAD?><?suppdata-mime-type application?><?suppdata-mime-sub-type vnd.openxmlformats-officedocument.wordprocessingml.document?><?suppdata-cloudpmc-urn urn:app:ac18/12371607/31473074bddb/JOCD-24-e70418-s003.docx?></media></supplementary-material></sec></body><back><ack id="jocd70418-sec-0019"><title>Acknowledgments</title><p>The authors have nothing to report.</p></ack><sec sec-type="data-availability" id="jocd70418-sec-0018"><title>Data Availability Statement</title><p>The authors have nothing to report.</p></sec><ref-list content-type="cited-references" id="jocd70418-bibl-0001"><title>References</title><ref id="jocd70418-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jocd70418-cit-0001">
<string-name name-style="western">
<given-names>D. K.</given-names>
<surname>Kerob</surname>
</string-name>, <string-name name-style="western">
<given-names>T.</given-names>
<surname>Passeron</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Alexis</surname>
</string-name>, et al., “<article-title>54728 Prevalence of Post‐Inflammatory Hyperpigmentation, Impact on Quality of Life and Social Stigmatization: Results of the First Large International Survey</article-title>,” <source>Journal of the American Academy of Dermatology</source>
<volume>91</volume>, no. <issue>3</issue> (<year>2024</year>): <elocation-id>AB73</elocation-id>.</mixed-citation></ref><ref id="jocd70418-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jocd70418-cit-0002">
<string-name name-style="western">
<given-names>B. P.</given-names>
<surname>Kaufman</surname>
</string-name>, <string-name name-style="western">
<given-names>T.</given-names>
<surname>Aman</surname>
</string-name>, and <string-name name-style="western">
<given-names>A. F.</given-names>
<surname>Alexis</surname>
</string-name>, “<article-title>Postinflammatory Hyperpigmentation: Epidemiology, Clinical Presentation, Pathogenesis and Treatment</article-title>,” <source>American Journal of Clinical Dermatology</source>
<volume>19</volume>, no. <issue>4</issue> (<year>2018</year>): <fpage>489</fpage>–<lpage>503</lpage>.<pub-id pub-id-type="pmid">29222629</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40257-017-0333-6</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jocd70418-cit-0003">
<string-name name-style="western">
<given-names>S. K.</given-names>
<surname>Chaturvedi</surname>
</string-name>, <string-name name-style="western">
<given-names>G.</given-names>
<surname>Singh</surname>
</string-name>, and <string-name name-style="western">
<given-names>N.</given-names>
<surname>Gupta</surname>
</string-name>, “<article-title>Stigma Experience in Skin Disorders: An Indian Perspective</article-title>,” <source>Dermatologic Clinics</source>
<volume>23</volume>, no. <issue>4</issue> (<year>2005</year>): <fpage>635</fpage>–<lpage>642</lpage>.<pub-id pub-id-type="pmid">16112439</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.det.2005.05.007</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jocd70418-cit-0004">
<string-name name-style="western">
<given-names>A. M.</given-names>
<surname>Thawabteh</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Jibreen</surname>
</string-name>, <string-name name-style="western">
<given-names>D.</given-names>
<surname>Karaman</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Thawabteh</surname>
</string-name>, and <string-name name-style="western">
<given-names>R.</given-names>
<surname>Karaman</surname>
</string-name>, “<article-title>Skin Pigmentation Types, Causes and Treatment—A Review</article-title>,” <source>Molecules</source>
<volume>28</volume>, no. <issue>12</issue> (<year>2023</year>): <elocation-id>4839</elocation-id>.<pub-id pub-id-type="pmid">37375394</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules28124839</pub-id><pub-id pub-id-type="pmcid">PMC10304091</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jocd70418-cit-0005">
<string-name name-style="western">
<given-names>A.</given-names>
<surname>Nautiyal</surname>
</string-name> and <string-name name-style="western">
<given-names>S.</given-names>
<surname>Wairkar</surname>
</string-name>, “<article-title>Management of Hyperpigmentation: Current Treatments and Emerging Therapies</article-title>,” <source>Pigment Cell &amp; Melanoma Research</source>
<volume>34</volume>, no. <issue>6</issue> (<year>2021</year>): <fpage>1000</fpage>–<lpage>1014</lpage>.<pub-id pub-id-type="pmid">33998768</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pcmr.12986</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jocd70418-cit-0006">
<string-name name-style="western">
<given-names>J.</given-names>
<surname>Yoo</surname>
</string-name>, “<article-title>Differential Diagnosis and Management of Hyperpigmentation</article-title>,” <source>Clinical and Experimental Dermatology</source>
<volume>47</volume>, no. <issue>2</issue> (<year>2022</year>): <fpage>251</fpage>–<lpage>258</lpage>.<pub-id pub-id-type="pmid">33999447</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ced.14747</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jocd70418-cit-0007">
<string-name name-style="western">
<given-names>E.</given-names>
<surname>Markiewicz</surname>
</string-name>, <string-name name-style="western">
<given-names>N.</given-names>
<surname>Karaman‐Jurukovska</surname>
</string-name>, <string-name name-style="western">
<given-names>T.</given-names>
<surname>Mammone</surname>
</string-name>, and <string-name name-style="western">
<given-names>O. C.</given-names>
<surname>Idowu</surname>
</string-name>, “<article-title>Post‐Inflammatory Hyperpigmentation in Dark Skin: Molecular Mechanism and Skincare Implications</article-title>,” <source>Clinical, Cosmetic and Investigational Dermatology</source>
<volume>15</volume> (<year>2022</year>): <fpage>2555</fpage>–<lpage>2565</lpage>.<pub-id pub-id-type="pmid">36466945</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CCID.S385162</pub-id><pub-id pub-id-type="pmcid">PMC9709857</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jocd70418-cit-0008">
<string-name name-style="western">
<given-names>K.</given-names>
<surname>Mar</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Maazi</surname>
</string-name>, <string-name name-style="western">
<given-names>B.</given-names>
<surname>Khalid</surname>
</string-name>, <string-name name-style="western">
<given-names>R.</given-names>
<surname>Ahmed</surname>
</string-name>, <string-name name-style="western">
<given-names>O. J.</given-names>
<surname>Wang</surname>
</string-name>, and <string-name name-style="western">
<given-names>T.</given-names>
<surname>Khosravi‐Hafshejani</surname>
</string-name>, “<article-title>Prevention of Post‐Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review</article-title>,” <source>Australasian Journal of Dermatology</source>
<volume>66</volume> (<year>2025</year>): <fpage>119</fpage>–<lpage>126</lpage>.<pub-id pub-id-type="pmid">39953770</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ajd.14432</pub-id><pub-id pub-id-type="pmcid">PMC12062726</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jocd70418-cit-0009">
<string-name name-style="western">
<given-names>K.</given-names>
<surname>Mar</surname>
</string-name>, <string-name name-style="western">
<given-names>B.</given-names>
<surname>Khalid</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Maazi</surname>
</string-name>, <string-name name-style="western">
<given-names>R.</given-names>
<surname>Ahmed</surname>
</string-name>, <string-name name-style="western">
<given-names>O. J.</given-names>
<surname>Wang</surname>
</string-name>, and <string-name name-style="western">
<given-names>T.</given-names>
<surname>Khosravi‐Hafshejani</surname>
</string-name>, “<article-title>Treatment of Post‐Inflammatory Hyperpigmentation in Skin of Colour: A Systematic Review</article-title>,” <source>Journal of Cutaneous Medicine and Surgery</source>
<volume>28</volume>, no. <issue>5</issue> (<year>2024</year>): <fpage>473</fpage>–<lpage>480</lpage>.<pub-id pub-id-type="pmid">39075672</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/12034754241265716</pub-id><pub-id pub-id-type="pmcid">PMC11514325</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jocd70418-cit-0010">
<string-name name-style="western">
<given-names>N.</given-names>
<surname>Kashetsky</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Feschuk</surname>
</string-name>, and <string-name name-style="western">
<given-names>M.</given-names>
<surname>Pratt</surname>
</string-name>, “<article-title>Post‐Inflammatory Hyperpigmentation: A Systematic Review of Treatment Outcomes</article-title>,” <source>Journal of the European Academy of Dermatology and Venereology</source>
<volume>38</volume>, no. <issue>3</issue> (<year>2024</year>): <fpage>470</fpage>–<lpage>479</lpage>.<pub-id pub-id-type="pmid">37843491</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jdv.19566</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jocd70418-cit-0011">
<string-name name-style="western">
<given-names>R.</given-names>
<surname>Evans</surname>
</string-name>, <string-name name-style="western">
<given-names>R.</given-names>
<surname>Marriott</surname>
</string-name>, and <string-name name-style="western">
<given-names>M.</given-names>
<surname>Harker</surname>
</string-name>, “<article-title>Axillary Skin: Biology and Care</article-title>,” <source>International Journal of Cosmetic Science</source>
<volume>34</volume>, no. <issue>5</issue> (<year>2012</year>): <fpage>389</fpage>–<lpage>395</lpage>.<pub-id pub-id-type="pmid">22612735</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1468-2494.2012.00729.x</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jocd70418-cit-0012">
<string-name name-style="western">
<given-names>I. G. C.</given-names>
<surname>Robredo</surname>
</string-name>, “<article-title>Q‐Switched 1064nm Nd:YAG Laser in Treating Axillary Hyperpigmentation in Filipino Women With Skin Types IV‐V</article-title>,” <source>Journal of Drugs in Dermatology</source>
<volume>19</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>66</fpage>–<lpage>69</lpage>.<pub-id pub-id-type="pmid">31985913</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.36849/JDD.2020.4623</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jocd70418-cit-0013">
<string-name name-style="western">
<given-names>A.</given-names>
<surname>James</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Pople</surname>
</string-name>, <string-name name-style="western">
<given-names>W.</given-names>
<surname>Parish</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Moore</surname>
</string-name>, and <string-name name-style="western">
<given-names>N.</given-names>
<surname>Dunbar</surname>
</string-name>, “<article-title>Histological Evaluation of Hyperpigmentation on Female Filipino Axillary Skin 1</article-title>,” <source>International Journal of Cosmetic Science</source>
<volume>28</volume>, no. <issue>4</issue> (<year>2006</year>): <fpage>247</fpage>–<lpage>253</lpage>.<pub-id pub-id-type="pmid">18489264</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1467-2494.2006.00328.x</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jocd70418-cit-0014">
<string-name name-style="western">
<given-names>M. J.</given-names>
<surname>Page</surname>
</string-name>, <string-name name-style="western">
<given-names>J. E.</given-names>
<surname>McKenzie</surname>
</string-name>, <string-name name-style="western">
<given-names>P. M.</given-names>
<surname>Bossuyt</surname>
</string-name>, et al., “<article-title>The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews</article-title>,” <source>BMJ</source>
<volume>372</volume> (<year>2021</year>): <elocation-id>n71</elocation-id>.<pub-id pub-id-type="pmid">33782057</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jocd70418-cit-0015">
<string-name name-style="western">
<given-names>J. P.</given-names>
<surname>Castanedo‐Cazares</surname>
</string-name>, <string-name name-style="western">
<given-names>G.</given-names>
<surname>Lárraga‐Piñones</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Ehnis‐Pérez</surname>
</string-name>, et al., “<article-title>Topical Niacinamide 4% and Desonide 0.05% for Treatment of Axillary Hyperpigmentation: A Randomized, Double‐Blind, Placebo‐Controlled Study</article-title>,” <source>Clinical, Cosmetic and Investigational Dermatology</source>
<volume>6</volume> (<year>2013</year>): <fpage>29</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">23355788</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CCID.S39246</pub-id><pub-id pub-id-type="pmcid">PMC3552481</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0016"><label>16</label><mixed-citation publication-type="miscellaneous" id="jocd70418-cit-0016">
<string-name name-style="western">
<given-names>P. T.</given-names>
<surname>Colpas</surname>
</string-name>, <string-name name-style="western">
<given-names>C. A.</given-names>
<surname>Miyashiro</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Schalka</surname>
</string-name>, and <string-name name-style="western">
<given-names>A. G.</given-names>
<surname>Neto</surname>
</string-name>, <article-title>“Evaluation of Efficacy and Safety of a Novel Cosmetic Serum for Axillary Hyperpigmentation</article-title>,” 24th World Congress of Dermatology (2019), Milan.</mixed-citation></ref><ref id="jocd70418-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jocd70418-cit-0017">
<string-name name-style="western">
<given-names>W.</given-names>
<surname>Preedalikit</surname>
</string-name>, <string-name name-style="western">
<given-names>K.</given-names>
<surname>Pintha</surname>
</string-name>, <string-name name-style="western">
<given-names>P.</given-names>
<surname>Tantipaiboonwong</surname>
</string-name>, <string-name name-style="western">
<given-names>N.</given-names>
<surname>Aunsri</surname>
</string-name>, <string-name name-style="western">
<given-names>P.</given-names>
<surname>Vivattanaseth</surname>
</string-name>, and <string-name name-style="western">
<given-names>L.</given-names>
<surname>Mungmai</surname>
</string-name>, “<article-title>Inhibitory Effect of Perilla Frutescens l. Leaves Extract on Melanogenesis and Skin Whitening Efficacy in the Underarm Whitening Product Application</article-title>,” <source>Key Engineering Materials</source>
<volume>859</volume> (<year>2020</year>): <fpage>166</fpage>–<lpage>171</lpage>.</mixed-citation></ref><ref id="jocd70418-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jocd70418-cit-0018">
<string-name name-style="western">
<given-names>G.</given-names>
<surname>Mohammed</surname>
</string-name>, “<article-title>Topical <italic toggle="yes">Cyperus rotundus</italic> Essential Oil for Treatment of Axillary Hyperpigmentation: A Randomized, Double‐Blind, Active‐ and Placebo‐Controlled Study</article-title>,” <source>Clinical and Experimental Dermatology</source>
<volume>47</volume>, no. <issue>3</issue> (<year>2022</year>): <fpage>534</fpage>–<lpage>541</lpage>.<pub-id pub-id-type="pmid">34618367</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ced.14959</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jocd70418-cit-0019">
<string-name name-style="western">
<given-names>S.</given-names>
<surname>Murlistyarini</surname>
</string-name> and <string-name name-style="western">
<given-names>N.</given-names>
<surname>Hidayah</surname>
</string-name>, “<article-title>Laporan Kasus: Terapi Kombinasi Krim Asam Glikolat 8% Dan Peeling Asam Glikolat 15% Pada Hiperpigmentasi Aksila: Serial Kasus Pada 2 Pasien</article-title>,” <source>Majalah Kesehatan</source>
<volume>9</volume>, no. <issue>3</issue> (<year>2022</year>): <fpage>171</fpage>–<lpage>180</lpage>.</mixed-citation></ref><ref id="jocd70418-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jocd70418-cit-0020">
<string-name name-style="western">
<given-names>F.</given-names>
<surname>Oei</surname>
</string-name>, <string-name name-style="western">
<given-names>I. B.</given-names>
<surname>Putra</surname>
</string-name>, and <string-name name-style="western">
<given-names>N. K.</given-names>
<surname>Jusuf</surname>
</string-name>, “<article-title>Efficacy of Sweet Orange Peels (<italic toggle="yes">Citrus sinensis</italic> l.) 0.1% Extract Cream on Improvement of Axillary Postinflammatory Hyperpigmentation</article-title>,” <source>F1000Research</source>
<volume>13</volume> (<year>2024</year>): <elocation-id>394</elocation-id>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.12688/f1000research.142199.1</pub-id><pub-id pub-id-type="pmcid">PMC11157189</pub-id><pub-id pub-id-type="pmid">38854441</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jocd70418-cit-0021">
<string-name name-style="western">
<given-names>S.</given-names>
<surname>Ghannam</surname>
</string-name>, <string-name name-style="western">
<given-names>F. K.</given-names>
<surname>Al Otabi</surname>
</string-name>, <string-name name-style="western">
<given-names>K.</given-names>
<surname>Frank</surname>
</string-name>, and <string-name name-style="western">
<given-names>S.</given-names>
<surname>Cotofana</surname>
</string-name>, “<article-title>Efficacy of Low‐Fluence Nd: YAG 1064 Nm Laser for the Treatment of Post‐Inflammatory Hyperpigmentation in the Axillary Area</article-title>,” <source>Journal of Drugs in Dermatology</source>
<volume>16</volume> (<year>2017</year>): <fpage>1118</fpage>–<lpage>1123</lpage>.<pub-id pub-id-type="pmid">29141060</pub-id>
</mixed-citation></ref><ref id="jocd70418-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jocd70418-cit-0022">
<string-name name-style="western">
<given-names>W.</given-names>
<surname>Amornpetkul</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Kanokrungsee</surname>
</string-name>, <string-name name-style="western">
<given-names>N.</given-names>
<surname>Kamanamool</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Udompataikul</surname>
</string-name>, and <string-name name-style="western">
<given-names>S.</given-names>
<surname>Rojhirunsakool</surname>
</string-name>, “<article-title>Comparison Between the Use of Intense Pulsed Light and Q‐Switched Neodymium‐Doped Yttrium Aluminum Garnet Laser for the Treatment of Axillary Hyperpigmentation</article-title>,” <source>Journal of Cosmetic Dermatology</source>
<volume>20</volume>, no. <issue>9</issue> (<year>2021</year>): <fpage>2785</fpage>–<lpage>2793</lpage>.<pub-id pub-id-type="pmid">33550634</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jocd.13981</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0023"><label>23</label><mixed-citation publication-type="book" id="jocd70418-cit-0023">
<string-name name-style="western">
<given-names>N.</given-names>
<surname>Jarritrum</surname>
</string-name>, <string-name name-style="western">
<given-names>W.</given-names>
<surname>Vichit</surname>
</string-name>, <string-name name-style="western">
<given-names>K.</given-names>
<surname>Kittigowittana</surname>
</string-name>, and <string-name name-style="western">
<given-names>N.</given-names>
<surname>Saewan</surname>
</string-name>, “<part-title>Comparative Clinical Study of the Effectiveness of IPL and AHA in Underarm Whitening Treatment</part-title>,” in <source>School of Cosmetic Science</source> (<publisher-name>Studypool</publisher-name>, <year>2014</year>).</mixed-citation></ref><ref id="jocd70418-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jocd70418-cit-0024">
<string-name name-style="western">
<given-names>J.</given-names>
<surname>Srivilai</surname>
</string-name>, <string-name name-style="western">
<given-names>P.</given-names>
<surname>Phimnuan</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Jaisabai</surname>
</string-name>, et al., “<article-title>Curcuma Aeruginosa Roxb. Essential Oil Slows Hair‐Growth and Lightens Skin in Axillae; a Randomised, Double Blinded Trial</article-title>,” <source>Phytomedicine</source>
<volume>25</volume> (<year>2017</year>): <fpage>29</fpage>–<lpage>38</lpage>.<pub-id pub-id-type="pmid">28190468</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phymed.2016.12.007</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0025"><label>25</label><mixed-citation publication-type="book" id="jocd70418-cit-0025">
<string-name name-style="western">
<given-names>J. P.</given-names>
<surname>Ortonne</surname>
</string-name> and <string-name name-style="western">
<given-names>J. J.</given-names>
<surname>Nordlund</surname>
</string-name>, “<part-title>Mechanisms That Cause Abnormal Skin Color</part-title>,” in <source>The Pigmentary System: Physiology and Pathophysiology</source> (<publisher-name>Wiley</publisher-name>, <year>2006</year>), <fpage>521</fpage>–<lpage>537</lpage>.</mixed-citation></ref><ref id="jocd70418-bib-0026"><label>26</label><mixed-citation publication-type="book" id="jocd70418-cit-0026">
<string-name name-style="western">
<given-names>E.</given-names>
<surname>Lawrence</surname>
</string-name>, <string-name name-style="western">
<given-names>H. A.</given-names>
<surname>Syed</surname>
</string-name>, and <string-name name-style="western">
<given-names>K. M.</given-names>
<surname>Al Aboud</surname>
</string-name>, “<part-title>Postinflammatory Hyperpigmentation</part-title>,” in <source>StatPearls</source> (<publisher-name>StatPearls Publishing</publisher-name>, <year>2024</year>).<pub-id pub-id-type="pmid">32644576</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jocd70418-cit-0027">
<string-name name-style="western">
<given-names>F.</given-names>
<surname>Ghorbani</surname>
</string-name>, <string-name name-style="western">
<given-names>P.</given-names>
<surname>Koohsari</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Yaseri</surname>
</string-name>, et al., “<article-title>Laser Hair Removal Complications and the Associated Risk Factors at a Tertiary Dermatology Center: A Case–Control Study</article-title>,” <source>Lasers in Medical Science</source>
<volume>39</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>218</fpage>.<pub-id pub-id-type="pmid">39145871</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10103-024-04169-x</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jocd70418-cit-0028">
<string-name name-style="western">
<given-names>F.</given-names>
<surname>Mohamadi</surname>
</string-name>, <string-name name-style="western">
<given-names>E.</given-names>
<surname>Pourgholi</surname>
</string-name>, <string-name name-style="western">
<given-names>S. M.</given-names>
<surname>Vahabi</surname>
</string-name>, et al., “<article-title>Comparative Analysis of Erbium: Glass 1550 Nm and Combined Erbium: YAG &amp; Nd: YAG Lasers for Perioral Rejuvenation: A Prospective Study</article-title>,” <source>Lasers in Medical Science</source>
<volume>40</volume>, no. <issue>1</issue> (<year>2025</year>): <fpage>1</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10103-025-04540-6</pub-id><pub-id pub-id-type="pmid">40537663</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jocd70418-cit-0029">
<string-name name-style="western">
<given-names>V.</given-names>
<surname>Lajevardi</surname>
</string-name>, <string-name name-style="western">
<given-names>H.</given-names>
<surname>Mahmoudi</surname>
</string-name>, <string-name name-style="western">
<given-names>F.</given-names>
<surname>Karimi</surname>
</string-name>, <string-name name-style="western">
<given-names>Y.</given-names>
<surname>Kalantari</surname>
</string-name>, and <string-name name-style="western">
<given-names>I.</given-names>
<surname>Etesami</surname>
</string-name>, “<article-title>Comparing QS Nd: YAG Laser Alone With Its Combination With Fractional Ablative er: YAG in Tattoo Removal</article-title>,” <source>Journal of Cosmetic Dermatology</source>
<volume>20</volume>, no. <issue>12</issue> (<year>2021</year>): <fpage>4078</fpage>–<lpage>4080</lpage>.<pub-id pub-id-type="pmid">33728764</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jocd.14076</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jocd70418-cit-0030">
<string-name name-style="western">
<given-names>Y.</given-names>
<surname>Ghane</surname>
</string-name>, <string-name name-style="western">
<given-names>N.</given-names>
<surname>Heidari</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Hosseini</surname>
</string-name>, et al., “<article-title>Efficacy and Safety of Lasers Versus Topical Medications for Acanthosis Nigricans and Pseudo‐Acanthosis Nigricans Treatment: A Systematic Review</article-title>,” <source>Lasers in Medical Science</source>
<volume>39</volume>, no. <issue>1</issue> (<year>2024</year>): <fpage>44</fpage>.<pub-id pub-id-type="pmid">38253899</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10103-024-03986-4</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jocd70418-cit-0031">
<string-name name-style="western">
<given-names>D. L.</given-names>
<surname>Bissett</surname>
</string-name>, <string-name name-style="western">
<given-names>K.</given-names>
<surname>Miyamoto</surname>
</string-name>, <string-name name-style="western">
<given-names>P.</given-names>
<surname>Sun</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Li</surname>
</string-name>, and <string-name name-style="western">
<given-names>C.</given-names>
<surname>Berge</surname>
</string-name>, “<article-title>Topical Niacinamide Reduces Yellowing, Wrinkling, Red Blotchiness, and Hyperpigmented Spots in Aging Facial Skin 1</article-title>,” <source>International Journal of Cosmetic Science</source>
<volume>26</volume>, no. <issue>5</issue> (<year>2004</year>): <fpage>231</fpage>–<lpage>238</lpage>.<pub-id pub-id-type="pmid">18492135</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1467-2494.2004.00228.x</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jocd70418-cit-0032">
<string-name name-style="western">
<given-names>N.</given-names>
<surname>Kahanek</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Gelbard</surname>
</string-name>, and <string-name name-style="western">
<given-names>A.</given-names>
<surname>Hebert</surname>
</string-name>, “<article-title>Desonide: A Review of Formulations, Efficacy and Safety</article-title>,” <source>Expert Opinion on Investigational Drugs</source>
<volume>17</volume>, no. <issue>7</issue> (<year>2008</year>): <fpage>1097</fpage>–<lpage>1104</lpage>.<pub-id pub-id-type="pmid">18549345</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/13543784.17.7.1097</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jocd70418-cit-0033">
<string-name name-style="western">
<given-names>A.</given-names>
<surname>Pandurangan</surname>
</string-name>, <string-name name-style="western">
<given-names>R. L.</given-names>
<surname>Khosa</surname>
</string-name>, and <string-name name-style="western">
<given-names>S.</given-names>
<surname>Hemalatha</surname>
</string-name>, “<article-title>Evaluation of Anti‐Inflammatory and Analgesic Activity of Root Extract of <italic toggle="yes">Solanum trilobatum</italic> Linn</article-title>,” <source>Iranian Journal of Pharmaceutical Research</source>
<volume>7</volume> (<year>2008</year>): <fpage>217</fpage>–<lpage>221</lpage>.</mixed-citation></ref><ref id="jocd70418-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jocd70418-cit-0034">
<string-name name-style="western">
<given-names>K.‐J.</given-names>
<surname>Soumaya</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Dhekra</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Fadwa</surname>
</string-name>, et al., “<article-title>Pharmacological, Antioxidant, Genotoxic Studies and Modulation of Rat Splenocyte Functions by <italic toggle="yes">Cyperus rotundus</italic> Extracts</article-title>,” <source>BMC Complementary and Alternative Medicine</source>
<volume>13</volume> (<year>2013</year>): <fpage>1</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">23388107</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1472-6882-13-28</pub-id><pub-id pub-id-type="pmcid">PMC3570401</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jocd70418-cit-0035">
<string-name name-style="western">
<given-names>E.‐Y.</given-names>
<surname>Hwang</surname>
</string-name>, <string-name name-style="western">
<given-names>D.‐H.</given-names>
<surname>Kim</surname>
</string-name>, <string-name name-style="western">
<given-names>J.‐Y.</given-names>
<surname>Hwang</surname>
</string-name>, et al., “<article-title>A Study on the Depigmenting Effect of <styled-content style="fixed-case" toggle="no">
<italic toggle="no">Carthamus tinctorius</italic>
</styled-content> Seed, Cyperus Rotundus and Schizonepeta Tenuifolia Extracts</article-title>,” <source>Korean Journal of Food Science and Technology</source>
<volume>44</volume>, no. <issue>1</issue> (<year>2012</year>): <fpage>76</fpage>–<lpage>81</lpage>.</mixed-citation></ref><ref id="jocd70418-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jocd70418-cit-0036">
<string-name name-style="western">
<given-names>M.</given-names>
<surname>Narda</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Trullas</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Brown</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Piquero‐Casals</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Granger</surname>
</string-name>, and <string-name name-style="western">
<given-names>G.</given-names>
<surname>Fabbrocini</surname>
</string-name>, “<article-title>Glycolic Acid Adjusted to pH 4 Stimulates Collagen Production and Epidermal Renewal Without Affecting Levels of Proinflammatory TNF‐Alpha in Human Skin Explants</article-title>,” <source>Journal of Cosmetic Dermatology</source>
<volume>20</volume>, no. <issue>2</issue> (<year>2021</year>): <fpage>513</fpage>–<lpage>521</lpage>.<pub-id pub-id-type="pmid">32583600</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jocd.13570</pub-id><pub-id pub-id-type="pmcid">PMC7891644</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jocd70418-cit-0037">
<string-name name-style="western">
<given-names>M.</given-names>
<surname>Addi</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Elbouzidi</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Abid</surname>
</string-name>, <string-name name-style="western">
<given-names>D.</given-names>
<surname>Tungmunnithum</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Elamrani</surname>
</string-name>, and <string-name name-style="western">
<given-names>C.</given-names>
<surname>Hano</surname>
</string-name>, “<article-title>An Overview of Bioactive Flavonoids From Citrus Fruits</article-title>,” <source>Applied Sciences</source>
<volume>12</volume>, no. <issue>1</issue> (<year>2021</year>): <elocation-id>29</elocation-id>.</mixed-citation></ref><ref id="jocd70418-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jocd70418-cit-0038">
<string-name name-style="western">
<given-names>H. A.</given-names>
<surname>El‐Nashar</surname>
</string-name>, <string-name name-style="western">
<given-names>M. I. G.</given-names>
<surname>El‐Din</surname>
</string-name>, <string-name name-style="western">
<given-names>L.</given-names>
<surname>Hritcu</surname>
</string-name>, and <string-name name-style="western">
<given-names>O. A.</given-names>
<surname>Eldahshan</surname>
</string-name>, “<article-title>Insights on the Inhibitory Power of Flavonoids on Tyrosinase Activity: A Survey From 2016 to 2021</article-title>,” <source>Molecules</source>
<volume>26</volume>, no. <issue>24</issue> (<year>2021</year>): <elocation-id>7546</elocation-id>.<pub-id pub-id-type="pmid">34946631</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules26247546</pub-id><pub-id pub-id-type="pmcid">PMC8705159</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jocd70418-cit-0039">
<string-name name-style="western">
<given-names>S. A.</given-names>
<surname>Ali</surname>
</string-name>, <string-name name-style="western">
<given-names>R. K.</given-names>
<surname>Choudhary</surname>
</string-name>, <string-name name-style="western">
<given-names>I.</given-names>
<surname>Naaz</surname>
</string-name>, and <string-name name-style="western">
<given-names>A. S.</given-names>
<surname>Ali</surname>
</string-name>, “<article-title>Understanding the Challenges of Melanogenesis: Key Role of Bioactive Compounds in the Treatment of Hyperpigmentory Disorders</article-title>,” <source>Journal of Pigmentary Disorders</source>
<volume>2</volume> (<year>2015</year>): <fpage>1</fpage>–<lpage>9</lpage>.</mixed-citation></ref><ref id="jocd70418-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jocd70418-cit-0040">
<string-name name-style="western">
<given-names>Y. J.</given-names>
<surname>Lee</surname>
</string-name>, <string-name name-style="western">
<given-names>H. J.</given-names>
<surname>Shin</surname>
</string-name>, <string-name name-style="western">
<given-names>T.‐K.</given-names>
<surname>Noh</surname>
</string-name>, <string-name name-style="western">
<given-names>K.‐H.</given-names>
<surname>Choi</surname>
</string-name>, and <string-name name-style="western">
<given-names>S.‐E.</given-names>
<surname>Chang</surname>
</string-name>, “<article-title>Treatment of Melasma and Post‐Inflammatory Hyperpigmentation by a Picosecond 755‐Nm Alexandrite Laser in Asian Patients</article-title>,” <source>Annals of Dermatology</source>
<volume>29</volume>, no. <issue>6</issue> (<year>2017</year>): <fpage>779</fpage>–<lpage>781</lpage>.<pub-id pub-id-type="pmid">29200769</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.5021/ad.2017.29.6.779</pub-id><pub-id pub-id-type="pmcid">PMC5705362</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="jocd70418-cit-0041">
<string-name name-style="western">
<given-names>N.</given-names>
<surname>Li</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Han</surname>
</string-name>, <string-name name-style="western">
<given-names>D.</given-names>
<surname>Hu</surname>
</string-name>, et al., “<article-title>Intense Pulsed Light Is Effective in Treating Postburn Hyperpigmentation and Telangiectasia in Chinese Patients</article-title>,” <source>Journal of Cosmetic and Laser Therapy</source>
<volume>20</volume>, no. <issue>7–8</issue> (<year>2018</year>): <fpage>436</fpage>–<lpage>441</lpage>.<pub-id pub-id-type="pmid">29452029</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14764172.2017.1418517</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="jocd70418-cit-0042">
<string-name name-style="western">
<given-names>A.</given-names>
<surname>Augustyniak</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Erkiert‐Polguj</surname>
</string-name>, and <string-name name-style="western">
<given-names>H.</given-names>
<surname>Rotsztejn</surname>
</string-name>, “<article-title>Variable Pulsed Light Treatment of Melasma and Post‐Inflammatory Hyperpigmentation—A Pilot Study</article-title>,” <source>Journal of Cosmetic and Laser Therapy</source>
<volume>17</volume>, no. <issue>1</issue> (<year>2015</year>): <fpage>15</fpage>–<lpage>19</lpage>.<pub-id pub-id-type="pmid">25265499</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/14764172.2014.968576</pub-id></mixed-citation></ref><ref id="jocd70418-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="jocd70418-cit-0043">
<string-name name-style="western">
<given-names>J.‐H.</given-names>
<surname>Park</surname>
</string-name>, <string-name name-style="western">
<given-names>J.‐I.</given-names>
<surname>Kim</surname>
</string-name>, and <string-name name-style="western">
<given-names>W.‐S.</given-names>
<surname>Kim</surname>
</string-name>, “<article-title>Treatment of Persistent Facial Postinflammatory Hyperpigmentation With Novel Pulse‐In‐Pulse Mode Intense Pulsed Light</article-title>,” <source>Dermatologic Surgery</source>
<volume>42</volume>, no. <issue>2</issue> (<year>2016</year>): <fpage>218</fpage>–<lpage>224</lpage>.<pub-id pub-id-type="pmid">26808182</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/DSS.0000000000000627</pub-id></mixed-citation></ref></ref-list></back></article>